{
    "nct_id": "NCT03858712",
    "official_title": "Nonrandomized Phase II Hybrid Type 3 Implementation Study: Feasibility and Acceptance of an EHR-embedded Oral Cancer Directed Therapy Toxicity and Adherence Program for Patients With Breast or Gastrointestinal Cancer",
    "inclusion_criteria": "* Adult age 18 or older\n* Male or Female\n* Scheduled visit at DF/HCC within the BOC or GCC\n* Diagnosis of advanced breast cancer or gastrointestinal cancer\n* Prescribed any OCDT within prior 5 days of screening\n* English as the primary language (as documented in the EHR, written or spoken, and patient interpreter needed flag = no)\n* Mobile number listed in EHR to allow participation in ePP portion of the study\n* Women of any pregnancy status\n* Patients diagnosed with an advanced cancer will be eligible to participate in the study until discontinuation of OCDT or death, whichever occurs first\n\nExclusion Criteria\n\n* Adults unable to provide verbal consent\n* Pediatric patients\n* Patients without access to a electronic device (including tablet, computer, aptop or smartphone)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}